Stephen Donald Wilton

USPTO Granted Patents = 46 (Patent Applications = 36)

EPO Patents = 8 (Patent Applications = 21)

Average Co-Inventor Count = 3.3

ph-index = 28

Forward Citations = 2,183(Granted Patents)

Location History:

Perth, AU (2021)
Murdoch, AU (2022 - 2023)
Applecross, AU (2010 - 2024)

Company Filing History:

36 out of 106

The University of Western Australia

Sarepta Therapeutics, Inc.

patents

5. 2 out of 893

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

patents

6. 2 out of 371

Beijing University of Technology

patents

7. 1 out of 106

Research Institute at Nationwide Children's Hospital

patents

where one patent can have more than one assignee

Years Active: 2010-2024

Loading Chart...

Areas of Expertise:

Facioscapulohumeral Muscular Dystrophy

Advanced Glycation End-Products

NEAT1 Associated Disease

Antisense Molecules

Exon Skipping

CFTR Function Restoration

Splicing Modulation

Multiple Sclerosis Treatment

46 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11898143 - Agents useful in treating facioscapulohumeral muscular dystrophy (2024-02-13),

2. 11674143 - Modulators and modulation of the receptor for advanced glycation end-products RNA (2023-06-13),

3. 11459563 - Treatment for NEAT1 associated disease (2022-10-04),

4. 11447776 - Antisense molecules and methods for treating pathologies (2022-09-20),

5. 11441148 - Modulators and modulation of the receptor for advanced glycation end-products RNA (2022-09-13),

6. RE48960 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2022-03-07),

7. 11236338 - Antisense-induced exon2 inclusion in acid alpha-glucosidase (2022-02-01),

8. 11053494 - Methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene (2021-07-06),

9. 10995337 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2021-05-04),

10. 10968450 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2021-04-06),

11. 10907157 - Agents useful in treating facioscapulohumeral muscular dystrophy (2021-02-02),

12. 10781451 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2020-09-22),

13. 10781450 - Antisense molecules and methods for treating pathologies (2020-09-22),

14. 10731156 - Restoration of the CFTR function by splicing modulation (2020-08-04),

15. RE47769 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2019-12-16),

Title: The Innovative Contributions of Stephen Donald Wilton in Muscular Dystrophy Research

Introduction

Stephen Donald Wilton, based in Applecross, Australia, is a prominent inventor recognized for his significant contributions to the field of medical research and biotechnology. With an impressive portfolio of 46 patents, Wilton has focused primarily on innovations aimed at addressing muscular dystrophies.

Latest Patents

Among his latest patents, Wilton has developed agents useful in treating facioscapulohumeral muscular dystrophy. These include antisense agents and RNA interference agents that target double homeobox 4 and double homeobox 4c. The methodologies provide new avenues for treating diseases by modulating gene expression. Another significant patent involves modulators for the receptor for advanced glycation end-products (RAGE). This patent describes an isolated or purified antisense oligonucleotide (AON) that modifies pre-mRNA splicing in RAGE, offering further insights into therapeutic applications for this receptor.

Career Highlights

Wilton's career has been marked by his association with esteemed institutions such as The University of Western Australia and Murdoch University. His work in these environments has facilitated groundbreaking research in genetic therapies and muscular disorders.

Collaborations

Throughout his extensive career, Stephen Wilton has collaborated with notable coworkers, including Sue Fletcher and Graham McClorey. These partnerships have further enriched his research endeavors, contributing to developments that are poised to make a real impact in the treatment of muscular dystrophies.

Conclusion

Stephen Donald Wilton continues to be a pivotal figure in the realm of biotechnology and medical research. His numerous patents and collaborative efforts underscore his commitment to advancing our understanding and treatment of muscular dystrophy, making him an influential inventor in this critical field. His work exemplifies the innovation needed to drive progress in healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.